4th Annual Amyloidosis Symposium: “Beyond the Thickened Heart - Cardiac Amyloidosis & HCM in Focus”

Course Overview

Cardiac Amyloidosis and Hypertrophic Cardiomyopathy (HCM) are increasingly recognized as a treatable cause of heart failure, yet significant gaps remain in early diagnosis, appropriate use of diagnostic pathways, and timely initiation of emerging therapies.

This multidisciplinary CME program is designed to address these challenges by providing clinicians with practical, evidence-based strategies to improve recognition, diagnosis, and management of cardiac amyloidosis and HCM. Advances in imaging, noninvasive diagnostic algorithms, and disease-modifying therapies, including transthyretin stabilizers and RNA-targeted treatments, have transformed care, but require enhanced clinician understanding for optimal implementation.

Participants will gain insights into identifying clinical “red flags,” differentiating ATTR and AL amyloidosis and HCM, interpreting advanced imaging, and selecting appropriate therapies. Through expert-led presentations and case-based discussions, this program aims to improve multidisciplinary coordination, enhance patient-centered care, and ultimately improve outcomes for patients with cardiac amyloidosis.

Target Audience

This activity is designed for cardiologists, nuclear medicine physicians and radiologists, nuclear technologists, neurologists and echocardiographers.

Learning Objectives

Upon completion of this activity, participants should be better able to:

1. Recognize clinical “red flags” and risk factors suggestive of cardiac amyloidosis and HCM to support earlier diagnosis.

2. Apply evidence-based diagnostic algorithms to differentiate ATTR and AL amyloidosis and HCM using appropriate laboratories and imaging modalities.

3. Interpret advanced cardiac imaging findings (e.g., echocardiographic strain, cardiac MRI, nuclear imaging) in the evaluation of suspected amyloidosis and HCM.

4. Evaluate and select appropriate disease-modifying therapies based on amyloidosis subtypes and HCM, disease stage, and patient-specific factors.

5. Optimize supportive and heart failure management strategies tailored to patients with cardiac amyloidosis.

6. Implement multidisciplinary care approaches to improve coordination among cardiology, hematology, and specialty services.

7. Address health disparities and incorporate genetic considerations into screening and management strategies.

8. Utilize clinical guidelines and emerging evidence to improve quality of care and patient outcomes.

Accreditation

In support of improving patient care, Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians: Rutgers Biomedical and Health Sciences designates this live activity for a maximum of 6 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

In order to obtain CE credit, participants must be formally registered for the program, actively participate in the activity, and complete the online evaluation.

A link to the evaluation will be emailed to participants no later than Thursday, August 20, 2026. CE certificates will be issued via email approximately 30 days after the evaluation has been completed.

Faculty

Sabahat Bokhari, MD, FACC, FASNC, Professor of Medicine, Program Director of Advanced Cardiac Imaging Fellowship - Rutgers Robert Wood Johnson Medical School; Director of Advanced Cardiovascular Imaging, RWJUH; Director of Amyloidosis Center of Excellence

Yasmin Hamirani, MD, FACC Associate Professor of Medicine, Rutgers Robert Wood Johnson Medical School, Director of Structural Imaging, Robert Wood Johnson University Hospital

Ruchika Bhargav, DO, Assistant Professor of Medicine, Rutgers Robert Wood Johnson Medical School

Michael Huang, DO, Assistant Professor of Medicine, Rutgers Robert Wood Johnson Medical School, Director of Critical Cardiovascular Unit, Robert Wood Johnson University Hospital

Billie Fyfe-Kirschner, MD, Professor of Pathology, Rutgers Robert Wood Johnson Medical School and Rutgers New Jersey Medical School, Interim Chair, Department of Pathology, Newark Beth Israel Medical Center

Mansi Shah, MD, Associate Professor of Medicine, Rutgers Cancer Institute, Core Faculty, Hematology-Oncology Fellowship Program, Rutgers Robert Wood Johnson Medical School

Shan Chen, MD, PhD, Associate Professor of Neurology; Director, Peripheral Neuropathy Program and GBS/CIDP Center of Excellence, Foundation International; Director, EMG Laboratory, Director, Spasticity Program; Director, ALS Multi-Disciplinary Clinic and Center of Excellence of ALS Association, Rutgers Robert Wood Johnson Medical School

Chonyang Albert, MD, FACC, FHFSA, Associate Professor of Medicine, Rutgers Robert Wood Johnson Medical School, Medical Director of LVAD and MCS, Robert Wood Johnson University Hospital

Ashok Chaudhary, MD, FACC, FSCAI, RPVI, Associate Professor of Medicine; Program Director, Interventional Cardiology Fellowship, Rutgers Robert Wood Johnson Medical School

Leonard Lee, MD, James W. Mackenzie M.D. Professor and Chair, Department of Surgery, Rutgers Robert Wood Johnson Medical School; Surgeon-in-Chief Robert Wood Johnson University Hospital

Lisa Salberg, CEO and Founder, Hypertrophic Cardiomyopathy Association

James Mills, MD, FACC, Associate Professor of Medicine, Director of General and Preventive Cardiology, Robert Wood Johnson Medical School

Maya Guglin, MD, PhD, FACC, Professor of Medicine - Rutgers Robert Wood Johnson Medical School, Section Chief, Advanced Heart Failure, Robert Wood Johnson University Hospital

Lance Berger, MD, FACC, Medical Director, Cardiovascular Program Development, Community Medical Center, RWJBH

Eman Rashid, MD, PhD, Division of Cardiology, Newark Beth Israel Medical Center

Conor Barrett, MD, MBA, Chief Clinical Officer, RWJBarnabas Health, Heart & Vascular Services

Kameswari Maganti, MD, FACC, FASE, Professor of Medicine, Section Chief, Non-Invasive Cardiology, Robert Wood Johnson Medical School

Disclosure: The relevant financial relationships of all individuals who affect the content of continuing education activities and any discussion of off-label/investigational uses will be disclosed to the audience at the time of the activity.

For more information, visit the Amyloid Center of Excellence